Besides other HIV prevention measures like the use of prevention PREP for Truvada, PEP and others there’s a new development, yet to be introduced in Uganda. The Lenacapavir HIV Prevention Injection that is given twice a year, every six months.…
Early this week, I had the privilege of watching my boss, Dr. Flavia Matovu Kiweewadeliver a 1-minute elevator pitch to the President during his visit to our exhibition stall at the Makerere University Research and Innovation Week that’s been running…
It’s a privilege to have met Daniel O’Day again, Chairman & CEO of Gilead Sciences Inc. at a meeting post CROI 2025 in Forster City, CA. Our conversation highlighted the importance of continued innovation and collaboration in HIV prevention and…
I wish to share with you my notes following Dr. Flavia Matovu Kiweewa‘s appearance on Radio One FM 90‘s Health Net show over the weekend ahead of #WorldAidsDay, to discuss Gilead Sciences twice yearly injectable Lenacapavir (LEN). Read More>>>
It was a pleasure catching up with Gilead Sciences‘ PURPOSE 1 protocol leadership following my presentation at the recently concluded CROI 2025 meeting in SanFrancisco. Read More>>>
This year’s cohort is exceptional. It marks the first time we are including women leaders from Southern African states, thereby expanding our impact beyond East Africa. Join me in welcoming this incredible group of 30 women leaders who are committed…
At CROI 2025, Dr. Flavia Matovu Kiweewa from MU-JHU Care LTD | MU-JHU Research Collaboration presented impactful research highlighting the power of choice in HIV prevention. Her study focused on F/TAF, a daily oral Pre-Exposure Prophylaxis (PrEP) option that offers…
Dr. Kiweewa highlighted the continued importance of traditional HIV prevention methods, including the ABC approach (Abstinence, Be faithful, and Condom use), while encouraging the adoption of new scientific interventions like Lenacapavir.Details here: Read More:>>>>>
Read more>>>>>
Read more>>>>
